Genome-wide association studies (GWAS) have transformed our understanding of glioma susceptibility, but individual studies have had limited power to identify risk loci. We performed a meta-analysis of existing GWAS and two new GWAS, which totaled 12,496 cases and 18,190 controls. We identified five new loci for glioblastoma (GBM) at 1p31.3 (rs12752552; P = 2.04 × 10−9, odds ratio (OR) = 1.22), 11q14.1 (rs11233250; P = 9.95 × 10−10, OR = 1.24), 16p13.3 (rs2562152; P = 1.93 × 10−8, OR = 1.21), 16q12.1 (rs10852606; P = 1.29 × 10−11, OR = 1.18) and 22q13.1 (rs2235573; P = 1.76 × 10−10, OR = 1.15), as well as eight loci for non-GBM tumors at 1q32.1 (rs4252707; P = 3.34 × 10−9, OR = 1.19), 1q44 (rs12076373; P = 2.63 × 10−10, OR = 1.23), 2q33.3 (rs7572263; P = 2.18 × 10−10, OR = 1.20), 3p14.1 (rs11706832; P = 7.66 × 10−9, OR = 1.15), 10q24.33 (rs11598018; P = 3.39 × 10−8, OR = 1.14), 11q21 (rs7107785; P = 3.87 × 10−10, OR = 1.16), 14q12 (rs10131032; P = 5.07 × 10−11, OR = 1.33) and 16p13.3 (rs3751667; P = 2.61 × 10−9, OR = 1.18). These data substantiate that genetic susceptibility to GBM and non-GBM tumors are highly distinct, which likely reflects different etiology.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $18.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
We are grateful to all of the patients and individuals for their participation, and we would also like to thank the clinicians and other hospital staff members, cancer registries and the study staff members in the respective centers who contributed to the blood sample and data collection.
The GICC was supported by grants from the US National Institutes of Health (NIH) (R01CA139020 (M.L.B. and B.S.M.), R01CA52689 (M.R.W.), R01CA52689 (M.L.B.) and P30CA125123 (M. Scheurer). Additional support was provided by the McNair Medical Institute (M. Scheurer) and the Population Sciences Biorepository at Baylor College of Medicine (M. Scheurer).
In Sweden, work was additionally supported by Acta Oncologica through the Royal Swedish Academy of Science (B.S.M.'s salary) and by the Swedish Research Council (B.S.M.) and the Swedish Cancer Foundation (B.S.M.). We are grateful to the National Clinical Brain Tumor Group and to all of the clinicians and research nurses throughout Sweden who identified all of the cases.
In the UK, funding was provided by Cancer Research UK (C1298/A8362 supported by the Bobby Moore Fund (R.S.H., B.K. and P.B.), the Wellcome Trust (R.S.H., B.K. and P.B.) and the DJ Fielding Medical Research Trust (R.S.H., B.K. and P.B.). The National Brain Tumor Study is supported by the National Cancer Research Network, and we acknowledge all clinicians and healthcare professionals who contributed to this initiative. The UK INTERPHONE study was supported by the European Union Fifth Framework Program 'Quality of Life and Management of Living Resources' (QLK4-CT-1999-01563) (A.S., M.J.S. and S.J.F.) and the International Union against Cancer (UICC) (A.S., M.J.S. and S.J.F.). The UICC received funds from the Mobile Manufacturers' Forum and the GSM Association. Provision of funds via the UICC was governed by agreements that guaranteed INTERPHONE's scientific independence (http://www.iarc.fr/ENG/Units/RCAd.html), and the views expressed in the paper are not necessarily those of the funders. The UK centers were also supported by the Mobile Telecommunications and Health Research (MTHR) Programme, and the Northern UK Centre (A.S., M.J.S. and S.J.F.) was supported by the Health and Safety Executive, Department of Health and Safety Executive and the UK Network Operators.
In France, funding was provided by the Ligue Nationale Contre le Cancer (J.-Y.D.), the Fondation ARC (M. Sanson), the Institut National du Cancer (INCa; PL046; (M. Sanson)), the French Ministry of Higher Education and Research and the program “Investissements d'avenir” ANR-10-IAIHU-06 (M. Sanson, J.-Y.D., M. Labussière, A.-L.D.S., P.G., K.M., A.I., K.H.-X. and K.L.). This study was additionally supported by a grant from Génome Québec, le Ministère de l'Enseignement supérieur, de la Recherche, de la Science et de la Technologie (MESRST) Québec (M. Lathrop) and McGill University (M. Lathrop).
In Germany, funding was provided to M. Simon and J. Schramm by the Deutsche Forschungsgemeinschaft (Si552, Schr285), the Deutsche Krebshilfe (70-2385-Wi2, 70-3163-Wi3, 10-6262) and BONFOR. Funding for the WTCCC was provided by the Wellcome Trust (076113 and 085475; M. Simon and J. Schramm). The KORA Ausburg studies are supported by grants from the German Federal Ministry of Education and Research (BMBF) and were mainly financed by the Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg. This work was financed by the German National Genome Research Network (NGFN) (S. Schreiber and H.E.-W.) and supported within the Munich Center of Health Sciences (MC Health) as part of LMUinnovativ (S. Schreiber and H.E.-W.). Generation of the German control data was partially supported by a grant of the German Federal Ministry of Education and Research (BMBF) through the Integrated Network IntegraMent (Integrated Understanding of Causes and Mechanisms in Mental Disorders), under the auspices of the e:Med research and funding concept (01ZX1314A) (M.M.N., S. Herms and S. Heilmann). M.M.N. is a member of the DFG-funded Excellence Cluster ImmunoSensation and received support from the Alfried Krupp von Bohlen und Halbach-Stiftung.
For the UK GWAS, we acknowledge the funders, organizations and individuals who contributed to the blood sample and data collection as listed in Hepworth et al.45. MD Anderson acknowledges the work of P. Adatto, F. Morice, H. Zhang, V. Levin, A.W.K. Yung, M. Gilbert, R. Sawaya, V. Puduvalli, C. Conrad, F. Lang and J. Weinberg from the Brain and Spine Center for the MDA GWAS. For the French study, we are indebted to A. Rahimian (Onconeurotek), A.M. Lekieffre and M. Brandel for help in collecting data and to Y. Marie for database support. For the German study, we are indebted to B. Harzheim (Bonn), S. Ott and A. Müller-Erkwoh (Bonn) for help with the acquisition of clinical data and to R. Mahlberg (Bonn), who provided technical support. The UK study made use of control genotyping data generated by the Wellcome Trust Case–Control Consortium. A full list of the investigators who contributed to the generation of the data is available from http://www.wtccc.org.uk. The MDA GWAS made use of control genotypes from the CGEMS prostate and breast cancer studies. A full list of the investigators who contributed to the generation of the data is available from http://cgems.cancer.gov/. French controls were taken from the SU.VI.MAX study. The German GWAS made use of genotyping data from three population control sources: KORA-gen39, the Heinz-Nixdorf RECALL study and POPGEN. The HNR cohort was established with the support of the Heinz-Nixdorf Foundation. F.D. received support from the BONFOR Programme of the University of Bonn, Germany.
The UCSF Adult Glioma Study was supported by the NIH (grant numbers R01CA52689 (M.R.W. and J.K.W.), P50CA097257 (M.R.W. and J.K.W.), R01CA126831 (J.K.W.) and R01CA139020 (M.R.W.)), the Loglio Collective (M.R.W. and J.K.W.), the National Brain Tumor Foundation (M.R.W.), the Stanley D. Lewis and Virginia S. Lewis Endowed Chair in Brain Tumor Research (M.R.W.), the Robert Magnin Newman Endowed Chair in Neuro-oncology (J.K.W.) and by donations from the families and friends of J. Berardi, H. Glaser, E. Olsen, R.E. Cooper and W. Martinusen. This project also was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH, through UCSF–CTSI grant UL1 RR024131 (UCSF CTSI). The contents of this work are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code section 103885, the National Cancer Institute's Surveillance, Epidemiology and End Results Program under contract HHSN261201000140C (awarded to the Cancer Prevention Institute of California), contract HHSN261201000035C (awarded to the University of Southern California) and contract HHSN261201000034C (awarded to the Public Health Institute), and the Centers for Disease Control and Prevention's National Program of Cancer Registries under agreement # U58DP003862-01 (awarded to the California Department of Public Health). The ideas and opinions expressed herein are those of the author(s), and endorsement by the State of California Department of Public Health, the National Cancer Institute and the Centers for Disease Control and Prevention, or their contractors and subcontractors, is not intended nor should be inferred. Other significant contributors for the UCSF Adult Glioma Study include M. Berger, P. Bracci, S. Chang, J. Clarke, A. Molinaro, A. Perry, M. Pezmecki, M. Prados, I. Smirnov, T. Tihan, K. Walsh, J. Wiemels and S. Zheng.
At Mayo, the authors wish to acknowledge the study participants and the clinicians and research staff at the participating medical centers, the Mayo Clinic Biobank and Biospecimens Accessioning and Processing Shared Resource (in particular its manager, M. Cicek). Work at the Mayo Clinic beyond the GICC was also supported by the NIH (grants P50CA108961 (B. O'Neill) and P30CA15083 (R. Diasio)), the National Institute of Neurological Disorders and Stroke (grant RC1NS068222Z (R.B.J.)), the Bernie and Edith Waterman Foundation (R.B.J.) and the Ting Tsung and Wei Fong Chao Family Foundation (R.B.J.).
The GliomaScan Consortium comprised (apart from authors listed in the author list): L.E.B. Freeman (Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA), S. Koutros (Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA), D. Albanes (Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA), K. Visvanathan (Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA), V.L. Stevens (Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, USA), R. Henriksson (Department of Radiation Sciences, Oncology, Umea University, Umea, Sweden), D.S. Michaud (Department of Public Health and Community Medicine, Tufts University Medical School, Boston, Massachusetts, USA), M. Feychting (Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden), A. Ahlbom (Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden), G.G. Giles (Cancer Epidemiology Centre, Cancer Council of Victoria, Melbourne, Victoria, Australia and Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, University of Melbourne, Melbourne, Victoria, Australia), R. Milne (Cancer Epidemiology Centre, Cancer Council of Victoria, Melbourne, Victoria, Australia and Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, University of Melbourne, Melbourne, Victoria, Australia), R. McKean-Cowdin (Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA), L. Le Marchand (Cancer Research Center, University of Hawaii, Honolulu, Hawaii, USA), M. Stampfer (Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA and Departments of Epidemiology and Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA), A.M. Ruder (National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Cincinnati, Ohio, USA), T. Carreon (National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Cincinnati, Ohio, USA), G. Hallmans (Department of Public Health and Clinical Medicine/Nutritional Research, Umea University, Umea, Sweden), A. Zeleniuch-Jacquotte (Division of Epidemiology, Department of Environmental Medicine, New York University School of Medicine, New York, New York, USA), J.M. Gaziano (Massachusetts Veteran's Epidemiology, Research and Information Center, Geriatric Research Education and Clinical Center, VA Boston Healthcare System, Boston, Massachusetts, USA), H.D. Sesso (Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA), M.P. Purdue (Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA), E. White (Fred Hutchinson Cancer Research Center, Seattle, Washington, USA and Department of Epidemiology, University of Washington, Seattle, Washington, USA) and J. Buring (Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA).
UK10K data generation and access was organized by the UK10K consortium and funded by the Wellcome Trust.
About this article
Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics
International Journal of Cancer (2019)